2023年的肥胖药物

IF 0.4 4区医学 Q4 ENDOCRINOLOGY & METABOLISM Nutrition Clinique et Metabolisme Pub Date : 2023-12-01 Epub Date: 2024-01-09 DOI:10.1016/S0985-0562(24)00015-3

Pierre Bel Lassen , Judith Aron-Wisnewsky

{"title":"2023年的肥胖药物","authors":"Pierre Bel Lassen , Judith Aron-Wisnewsky","doi":"10.1016/S0985-0562(24)00015-3","DOIUrl":null,"url":null,"abstract":"<div><div>Significant progress have been made in the management of obesity thanks to the emergence of effective drug treatments, combined with dietary advice and regular physical activity. Unlike previous drugs tested, these new therapies allow for significant weight loss without serious side effects. They act primarily by increasing feelings of satiety and reducing food intake without frustration. GLP1 receptor agonists, such as liraglutide and semaglutide, are already recommended therapeutic options for the management of obesity in France. This review examines the mechanisms, efficacy, and side effects of the main drugs currently available on prescription.</div><div>© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).</div><div>Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":54702,"journal":{"name":"Nutrition Clinique et Metabolisme","volume":"37 2","pages":"Pages 2S70-2S73"},"PeriodicalIF":0.4000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Actualités de la pharmacothérapie de l’obésité en 2023\",\"authors\":\"Pierre Bel Lassen , Judith Aron-Wisnewsky\",\"doi\":\"10.1016/S0985-0562(24)00015-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Significant progress have been made in the management of obesity thanks to the emergence of effective drug treatments, combined with dietary advice and regular physical activity. Unlike previous drugs tested, these new therapies allow for significant weight loss without serious side effects. They act primarily by increasing feelings of satiety and reducing food intake without frustration. GLP1 receptor agonists, such as liraglutide and semaglutide, are already recommended therapeutic options for the management of obesity in France. This review examines the mechanisms, efficacy, and side effects of the main drugs currently available on prescription.</div><div>© 2023 Société francophone nutrition clinique et métabolisme (SFNCM).</div><div>Published by Elsevier Masson SAS. All rights reserved.</div></div>\",\"PeriodicalId\":54702,\"journal\":{\"name\":\"Nutrition Clinique et Metabolisme\",\"volume\":\"37 2\",\"pages\":\"Pages 2S70-2S73\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nutrition Clinique et Metabolisme\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0985056224000153\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition Clinique et Metabolisme","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0985056224000153","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/9 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

由于出现了有效的药物治疗方法，再加上饮食建议和定期体育锻炼，肥胖管理已经取得了重大进展。与之前测试过的药物不同，这些新疗法可以在没有严重副作用的情况下显著减轻体重。他们主要通过增加饱腹感和减少食物摄入量而不感到沮丧。GLP1受体激动剂，如利拉鲁肽和西马鲁肽，在法国已经被推荐用于治疗肥胖。本文综述了目前处方上可获得的主要药物的作用机制、疗效和副作用。©2023法国社会组织（SFNCM）。Elsevier Masson SAS出版。版权所有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Actualités de la pharmacothérapie de l’obésité en 2023

Significant progress have been made in the management of obesity thanks to the emergence of effective drug treatments, combined with dietary advice and regular physical activity. Unlike previous drugs tested, these new therapies allow for significant weight loss without serious side effects. They act primarily by increasing feelings of satiety and reducing food intake without frustration. GLP1 receptor agonists, such as liraglutide and semaglutide, are already recommended therapeutic options for the management of obesity in France. This review examines the mechanisms, efficacy, and side effects of the main drugs currently available on prescription.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nutrition Clinique et Metabolisme 医学-内分泌学与代谢

CiteScore

0.80

自引率

16.70%

发文量

216

审稿时长

78 days

期刊介绍： Nutrition Clinique et Métabolisme is the journal of the French-speaking Society of Enteral and Parenteral Nutrition. Associating clinicians, biologists, pharmacists, and fundamentalists, the articles presented in the journal concern man and animals, and deal with organs and cells. The goal is a better understanding of the effects of artificial nutrition and human metabolism. Original articles, general reviews, update articles, technical notes and communications are published, as well as editorials and case reports.